scholarly journals The Significance of Soy Protein and Soy Bioactive Compounds in the Prophylaxis and Treatment of Osteoporosis

2010 ◽  
Vol 2010 ◽  
pp. 1-8 ◽  
Author(s):  
Sa'eed Bawa
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Soy Protein ◽  
Bone Fragility ◽  
Urinary Calcium ◽  
Urinary Calcium Excretion ◽  
Sufficient Evidence ◽  
Calcium Excretion ◽  
Mineral Density ◽  
Post Menopausal

Osteoporosis is defined as a progressive systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Although bone mass and quality is mainly determined genetically, many other factors, including lifestyle and nutrition also have an impact on bone health. It has been suggested that dietary protein intake may be a risk factor for osteoporosis, and high-protein diets are associated with increased bone loss. Many scientists have examined the relationship between types of protein and urinary calcium excretion, and found that although animal protein was associated with increased urinary calcium excretion, soy protein was not. There is sufficient evidence suggesting soy isoflavones may have potential benefits for bone. Soy protein with naturally occurring phytoestrogens, mainly isoflavones protect against bone loss and synthetic soy ipriflavone in some studies has been shown to favorably affect, but a cause and effect relationship has not been established between the consumption of ipriflavone and maintenance of bone mineral density in post-menopausal women. Therefore it is too early to recommend it as a supplement for this group of women.

scholarly journals Bone and Mineral Metabolism in Patients with Primary Aldosteronism

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Luigi Petramala ◽  
Laura Zinnamosca ◽  
Amina Settevendemmie ◽  
Cristiano Marinelli ◽  
Matteo Nardi ◽  
...  
Keyword(s):  
Vitamin D ◽  
Primary Aldosteronism ◽  
Mineral Metabolism ◽  
Urinary Calcium ◽  
Urinary Calcium Excretion ◽  
Calcium Excretion ◽  
Mineral Density ◽  
Lower Serum ◽  
Functional Link ◽  
The Impact

Primary aldosteronism represents major cause of secondary hypertension, strongly associated with high cardiovascular morbidity and mortality. Aldosterone excess may influence mineral homeostasis, through higher urinary calcium excretion inducing secondary increase of parathyroid hormone. Recently, in a cohort of PA patients a significant increase of primary hyperparathyroidism was found, suggesting a bidirectional functional link between the adrenal and parathyroid glands. The aim of this study was to evaluate the impact of aldosterone excess on mineral metabolism and bone mass density. In 73 PA patients we evaluated anthropometric and biochemical parameters, renin-angiotensin-aldosterone system, calcium-phosphorus metabolism, and bone mineral density; control groups were 73 essential hypertension (EH) subjects and 40 healthy subjects. Compared to HS and EH, PA subjects had significantly lower serum calcium levels and higher urinary calcium excretion. Moreover, PA patients showed higher plasma PTH, lower serum 25(OH)-vitamin D levels, higher prevalence of vitamin D deficiency (65% versus 25% and 25%;P<0.001), and higher prevalence of osteopenia/osteoporosis (38.5 and 10.5%) than EH (28% and 4%) and NS (25% and 5%), respectively. This study supports the hypothesis that bone loss and fracture risk in PA patients are potentially the result of aldosterone mediated hypercalciuria and the consecutive secondary hyperparathyroidism.

scholarly journals An epidemiological study to assess bone mineral density and its association with contributing factors among premenopausal and postmenopausal women in selected villages of District Shimla, Himachal Pradesh, India

2018 ◽  
Vol 7 (2) ◽  
pp. 487 ◽  
Author(s):  
Nancy Garg ◽  
Viji Mol G. ◽  
Deepika Sethi
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Economic Status ◽  
Premenopausal Women ◽  
Research Approach ◽  
Contributing Factors ◽  
Mineral Density ◽  
Menopausal Women ◽  
Post Menopausal

Background: Development of peak bone mass and premenopausal bone loss is determined by the menstrual status of women. Decline in bone mass with age becomes accelerated during menopause. Menopausal bone loss refers to the accelerated bone loss that occurs during the BM) of premenopausal and post-menopausal women, to identify the contributing factors associated with BMD among pre and post-menopausal women, to compare the level of BMD and the contributing factors of pre-menopausal women with post-menopausal women.Methods: It was quantative research approach and epidemiological analytic research design was used. Total enumeration technique was adopted in this study.Results: Analysis of data was done in accordance with the objectives of the study. Findings show that among premenopausal women 45.10% of the women had osteopenia and 8.20% of the women had osteoporosis, among postmenopausal women 50.00% of the women had oestriopenic and 41.2% of the women had osteoporosis. The analysis shows that factors such as BMI, Health status, life style, age, economic status and dietary patter plays important role to accelerate the level of T-score more than -1 in both group either premenopausal women or post-menopausal women. It shows the significance at the level of p<0.001.Conclusions: The study was completed in July 2016, concludes that there are many factors that can lead to have risk of osteoporosis related fracture. As age is increased the risk is also increased to get the fracture. Every woman can go for screening of BMD test to control the risk of fracture.

scholarly journals Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety

2019 ◽  
Vol 104 (11) ◽  
pp. 5601-5610 ◽  
Author(s):  
Yu-Kwang Donovan Tay ◽  
Gaia Tabacco ◽  
Natalie E Cusano ◽  
John Williams ◽  
Beatriz Omeragic ◽  
...  
Keyword(s):  
Vitamin D ◽  
Renal Function ◽  
Calcium Phosphate ◽  
Serum Calcium ◽  
Urinary Calcium ◽  
Urinary Calcium Excretion ◽  
Calcium Excretion ◽  
Mineral Density ◽  
Supplemental Calcium ◽  
Phosphate Product

Abstract Context Conventional treatment of hypoparathyroidism is associated with decreased renal function and increased bone mineral density (BMD). Objective To evaluate the effects of 8 years of recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] therapy on key biochemical and densitometric indices. Design Prospective open-label trial. Setting Tertiary medical center. Participants Twenty-four subjects with hypoparathyroidism. Intervention Treatment with rhPTH(1-84) for 8 years. Main Outcome Measures Supplemental calcium and vitamin D requirements, serum calcium and phosphorus levels, calcium-phosphate product, urinary calcium excretion, estimated glomerular filtration rate (eGFR) and BMD. Results PTH therapy was associated with progressive reduction in supplemental calcium (57%; P < 0.01) and active vitamin D (76%; P < 0.001) requirements over 8 years. Serum calcium concentration was stable; urinary calcium excretion declined 38% (P < 0.01). eGFR remained stable and was related to baseline eGFR and serum calcium levels. Calcium-phosphate product was below the recommended limit; serum phosphorus remained within normal range. Lumbar spine and total hip BMD increased, peaking at 4 (mean ± SE, 4.6% ± 1.5%; P = 0.01) and 8 years (2.6% ± 1.1%; P = 0.02), whereas femoral neck BMD did not change and one-third radius BMD decreased (mean ± SE, −3.5% ± 1.1%; P = 0.001). BMD at all sites was higher throughout the 8 years than in the age- and sex-matched reference population. Hypercalcemia and hypocalcemia were uncommon. Conclusion rhPTH(1-84) is a safe and effective treatment for hypoparathyroidism for 8 years. Long-term reductions in supplemental requirements and biochemical improvements with stable renal function are maintained.

scholarly journals Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis

2003 ◽  
Vol 149 (3) ◽  
pp. 209-213 ◽  
Author(s):  
S Giannini ◽  
M Nobile ◽  
L Dalle Carbonare ◽  
MG Lodetti ◽  
S Sella ◽  
...  
Keyword(s):  
Bone Density ◽  
Bone Loss ◽  
Bone Mass ◽  
Urinary Calcium ◽  
Bone Diseases ◽  
Calcium Excretion ◽  
Primary Osteoporosis ◽  
Low Bone Mass ◽  
Metabolic Bone Diseases ◽  
Metabolic Bone

OBJECTIVE AND DESIGN: The prevalence and the effects of hypercalciuria on bone in patients with primary osteoporosis are poorly defined. We therefore retrospectively analyzed the data of 241 otherwise healthy women. They were 45-88 years of age and had been referred for their first visit to our Unit for Metabolic Bone Diseases over a 2-year period because of primary osteoporosis (bone density T-score < -2.5). METHODS: The main parameters of calcium and skeletal metabolism had been analyzed in all subjects. This population was then divided into two groups, according to the presence (HC+) or absence (HC-) of hypercalciuria. RESULTS: Elevated urinary calcium was present in 19% of the subjects. Due to the selection criteria, spinal and femoral bone loss was similar in the two groups. Urinary calcium, phosphate and fractional calcium excretion were higher in hypercalciuric patients. In a logistic regression model, the higher the Tm of phosphate, the lower the risk of hypercalciuria (odds ratio 0.33, confidence interval 0.18-0.62). On the contrary, hypercalciuria was the most important predictor of low bone mass in HC+ (accounting for more than 50% of the variance in spinal bone density). CONCLUSIONS: Hypercalciuria is a common feature in postmenopausal bone loss. Since increased urinary calcium excretion and low bone mass appear to be linked, hypercalciuria seems to be an important determinant of reduced bone density in this setting as well.

Sign in / Sign up

Export Citation Format

Share Document